ARCHIMED (MED Platform I) Acquires Majority Stake in CARSO

ARCHIMED-backed CARSO Acquires Arace Laboratori, AQCF and Three Asbestos Testing Labs

May 6, 2024

Healthcare Services

ARCHIMED, together with partners CAPZA Flex Equity Mid‑Market and Siparex, funded three concurrent add-on acquisitions by CARSO: Italian Arace Laboratori, French food‑safety specialist AQCF, and a grouping of three asbestos testing laboratories carved out from AC Environnement. The deals, financed by equity from shareholders and a debt facility arranged by Tikehau Capital, strengthen CARSO's position as France's market leader in health‑at‑work and purity testing and accelerate its European consolidation strategy.

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

CARSO Group Acquires Agro.Biolab Laboratory (Italy)

March 16, 2023

Healthcare Services

French lab testing leader CARSO Group has acquired Agro.Biolab Laboratory, a Bari-based Italian food-safety testing company. The add-on was financed by CARSO's majority owner ARCHIMED with partners CAPZA Flex Equity Mid-Market and Siparex; the Agro.Biolab founder's family will roll over a significant portion of proceeds into a minority stake in CARSO.

ARCHIMED Acquires Majority Stake in Cardioline

November 17, 2021

Medical Devices

Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ArchiMed Acquires Majority Stake in NAMSA

September 1, 2020

Healthcare Services

ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.